Skip to main content
Bavarian Nordic logo

Bavarian Nordic — Investor Relations & Filings

Ticker · BAVA ISIN · DK0015998017 LEI · 2138006JCDVYIN6INP51 CO Manufacturing
Open in API
Filings indexed 2,303 across all filing types
Latest filing 2023-08-23 Earnings Release
Country DK Denmark
Listing CO BAVA

About Bavarian Nordic

https://www.bavarian-nordic.com/

Bavarian Nordic is a fully integrated biotechnology company specializing in the research, development, manufacturing, and commercialization of life-saving vaccines. The company's portfolio targets infectious diseases, including vaccines for Mpox, rabies, and typhoid. It is a leading global provider of travel vaccines and serves as a key partner for governments and international organizations in addressing public health preparedness needs.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 100% confidence The document is titled "Bavarian Nordic Announces First Half 2023 Results" and contains key financial highlights (Revenue, EBITDA) for the first half (H1 2023) and the second quarter (Q2 2023). It explicitly discusses interim financial results and includes a financial calendar listing the 'Half-year report (Q2)' release date. This content strongly indicates a report covering a period shorter than a full year, fitting the definition of an Interim/Quarterly Report (IR). Although it announces the results, the text provides substantial detail, including segment revenue breakdowns and management commentary, making it more than just a simple announcement (RPA). The presence of the attachment link to the 'Interim Report H1 2023' confirms the nature of the underlying document being summarized/announced, but the primary classification for this type of detailed release summarizing interim financials is IR. H1 2023
2023-08-23 English
Bavarian Nordic Announces First Half 2023 Results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Bavarian Nordic for the first half (H1) of 2023. It contains detailed financial statements, including income statements, balance sheets, cash flow statements, and management's review of financial performance. It is not merely an announcement (RPA) because it provides substantive financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-23 English
Bavarian Nordic Announces First Half 2023 Results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive interim financial report for Bavarian Nordic for the first half of 2023. It contains detailed financial statements, consolidated key figures, management's review, and commercial updates. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a 10-K as it covers a period shorter than a full fiscal year. Therefore, it is classified as an Interim / Quarterly Report. H1 2023
2023-08-23 English
Earnings Release 2023
Earnings Release Classification · 95% confidence The document is a press release from Bavarian Nordic announcing positive top-line results from a Phase 3 clinical trial for its chikungunya vaccine candidate. It details the trial endpoints, immunogenicity data, tolerability, and plans for regulatory submission in 2024. This type of announcement, focusing on the initial release of key financial or clinical performance data, aligns best with the 'Earnings Release' (ER) definition, even though it pertains to clinical trial results rather than quarterly financial earnings. It is a summary announcement, not the full clinical study report or a general regulatory filing. The document length (7800 chars) is substantial enough to be the primary announcement, not just a brief RPA. Since it is a release of key performance results, ER is the most appropriate fit among the provided options, as it serves the function of an initial results announcement. Q3 2023
2023-08-06 Danish
Earnings Release 2023
Earnings Release Classification · 99% confidence The document is a press release titled "Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents." It details the results of a clinical trial, mentions regulatory submissions planned for 2024, and announces a conference call. This content structure—announcing key clinical trial outcomes and financial/operational milestones outside of a standard periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press announcement. Since it focuses on key operational results (clinical trial success) rather than just financial figures, and it is a formal announcement of results, it aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical results or significant operational updates. It is not a full Annual Report (10-K), an Interim Report (IR), or a mere announcement of a report publication (RPA). FY 2023
2023-08-06 English
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Bavarian Nordic regarding positive Phase 3 clinical trial results for a chikungunya vaccine. It details the trial outcomes, provides management commentary, and includes information about an upcoming investor conference call. This type of announcement, which reports on operational/clinical progress rather than financial earnings or a specific regulatory filing, is best classified as a general regulatory announcement (RNS) within the provided framework.
2023-08-06 Danish

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.